查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1268950

全球疫苗佐剂市场 - 2023-2030

Global Vaccine Adjuvants Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

全球疫苗佐剂市场预计将出现利润丰厚的增长，到 2022 年将达到 7.397 亿美元，到 2030 年将达到 18.192 亿美元。 全球疫苗佐剂市场预计在预测期内（2023-2030 年）的复合年增长率为 12.2%。 涉及疫苗佐剂的市场参与者正在推进新产品的开发，预计这将在未来几年推动疫苗佐剂市场的增长。

例如，2021 年 10 月，生物製药公司 Dynavax Technologies Corporation 专注于疫苗的开发和商业化。 美国国防部 (DOD) 宣布 Dynavac 已获得一份价值约 2200 万美元的合同，为期两年半，用于开发重组 CpG 1018 佐剂鼠疫疫苗。 根据该协议，Dynavacs 将进行 2 期临床试验，将 CpG 1018 佐剂与 DOD 的 rF1V 疫苗相结合。 公司将于2022年开始二期临床试验。

全球疫苗佐剂市场受到传染病流行、对更有效疫苗的需求以及因 COVID-19 大流行而不断增长的疫苗需求的推动。 由于在开发新的有效疫苗时对疫苗佐剂的需求不断增加，预计全球疫苗佐剂市场将出现显着增长。

市场动态

传染病流行带动全球疫苗佐剂市场增长

在预测期内，由于全球传染病流行的加剧，预计全球疫苗佐剂市场的增长将会加快。 例如，疫苗接种是预防传染病最有效的策略之一。 结核病是继 COVID-19 之后世界上最致命的传染病之一，耐药结核分枝桿菌仍然是一个主要问题。

例如，美国疾病控制和预防中心报告称，2022 年美国将有 8,300 例确诊的结核病病例。 坚持结核病的人数约为每 100,000 人 2.5 例。 因此，这些原因将增加疫苗中佐剂的使用，推动全球疫苗佐剂市场的增长。

辅助开发的高研发成本阻碍了市场增长

製造商面临的主要挑战之一是与开发新疫苗佐剂相关的高研发成本。 研发和临床试验成本高昂，需要获得投资回报，这可能会成为十年或更长时间的资本限制。

单一疫苗的研发成本基线估计（通常指新药开发成本）在 10 亿美元到 20 亿美元之间。 这些高成本的原因是高失败率（经常被引用的是，FDA 批准了 5,000 到 10,000 种筛选化合物中的 1 种）。

COVID-19 影响分析

COVID-19 大流行对疫苗产生了前所未有的需求，而佐剂在增强这些疫苗的功效方面发挥着重要作用。 例如，Pfizer-BioNTech 疫苗和 Moderna COVID-19 疫苗都使用佐剂来增强人体对疫苗的免疫反应。 这在短期内推动了全球疫苗佐剂市场的增长。

然而，由于世界各地的旅行限制和封锁，疫苗佐剂的运输和分配一直很困难。 结果导致特异性佐剂短缺，延误了一些疫苗的研发和生产。 例如，Bharat Biotech 的 Covaxin 因佐剂短缺而面临供应链中断，减缓了在一些国家的分销。

俄乌衝突分析

全球疫苗佐剂市场可能会受到俄罗斯和乌克兰之间持续衝突的影响。 这是因为俄罗斯是氢氧化铝的主要供应商，氢氧化铝是疫苗中常用的一种佐剂。 由于衝突而中断这些佐剂的供应链可能导致佐剂依赖性疫苗的短缺。

内容

第 1 章研究方法和范围

  • 调查方法
  • 调查目的和范围

第 2 章定义和概述

第 3 章执行摘要

  • 按产品类型分类的摘要
  • 按给药途径分类的片段
  • 疾病片段
  • 最终用户的片段
  • 区域摘要

第四章市场动态

  • 影响因素
    • 司机
      • 在预测期内，传染病的流行推动了全球疫苗佐剂市场的增长
    • 约束因素
      • 辅助开发的高研发成本阻碍了市场增长
    • 机会
    • 影响分析

第五章行业分析

  • 波特的五力分析
  • 供应链分析
  • 价格分析
  • 监管分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • 在 COVID-19 情景之前
    • 当前的 COVID-19 情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 结论

第 7 章按产品类型

  • 颗粒佐剂
  • 佐剂乳液
  • 病原体成分
  • 伴随佐剂
  • 其他

第8章给药途径

  • 肌肉注射
  • 口语
  • 皮内
  • 皮下
  • 鼻内

第9章疾病

  • 感染
  • 癌症
  • 其他

第 10 章最终用户

  • 製药和生物技术公司
  • 关于研究机构
  • 其他

第11章按地区

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第12章竞争格局

  • 竞争场景
  • 市场分析/份额分析
  • 併购分析

第13章公司简介

  • InvivoGen
    • 公司简介
    • 产品组合和说明
    • 财务摘要
    • 主要发展
  • OZ Biosciences
  • SEPPIC
  • SPI Pharma
  • Agenus, Inc
  • Aphios Corp
  • Vaxine Pty Ltd
  • Seqirus
  • Chemtrade
  • Croda International

第14章 附录

简介目录
Product Code: PH1707

Market Overview

The global vaccine adjuvants market reached US$ 739.7 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 1,819.2 million by 2030. The global vaccine adjuvants market is expected to exhibit a CAGR of 12.2% during the forecast period (2023-2030). Market players involved in vaccine adjuvants are developing new products, which is expected to promote vaccine adjuvants market growth in the coming years.

For instance, in October 2021, Dynavax Technologies Corporation, a biopharmaceutical company, focused on developing and commercializing vaccines. The U.S. Department of Defense (DOD) announced that Dynavax had executed an agreement for approximately $22 million over two and a half years to develop a recombinant plague vaccine adjuvanted with CpG 1018. Under the agreement, Dynavax will conduct a Phase 2 clinical trial combining its CpG 1018 adjuvant with the DOD's rF1V vaccine. The company commenced the Phase 2 trial in 2022.

The global vaccine adjuvants market is being driven by the growing prevalence of infectious diseases, the need for more effective vaccines, and the rising demand for vaccines due to the COVID-19 pandemic. The global vaccine adjuvants market is expected to have significant growth due to increasing demand for vaccine adjuvants in the development of new and effective vaccines.

Market Dynamics

The increasing prevalence of infectious diseases to drive global vaccine adjuvants market growth

An increase in the prevalence of infectious diseases across the globe is expected to augment the growth of the global vaccine adjuvants market during the forecast period. For instance, vaccination is one of the most efficient strategies for the prevention of infectious diseases. Tuberculosis (TB) is one of the world's deadliest infectious diseases, second only to COVID-19, and drug-resistant TB strains are still a major concern.

For instance, according to the Centers for Disease Control and Prevention report, 8,300 TB cases were observed in the U.S. in 2022. Also, the incidene of TB adherence was about 2.5 cases per 100,000 persons. Therefore, owing to these reasons, the usage of adjuvants in vaccines will increase, thereby boosting the global vaccine adjuvants market growth.

High R&D cost for adjuvant development to hamper the market growth

One of the major challenges faced by the manufacturers is the high research & development cost associated with developing a new vaccine adjuvant. Costs associated with research, development, and clinical studies are high, and the company has to recoup its investment which could have tied up capital for a decade or more.

The estimated R&D cost for a single vaccine is often based on development costs for new drugs and is in the range US$ 1-2 billion. A reason for these high costs is high failure rates (it is often cited that only 1 in every 5,000-10,000 compounds screened is approved by the FDA).

COVID-19 Impact Analysis

The COVID-19 pandemic has led to an unprecedented demand for vaccines, and adjuvants have played a critical role in enhancing the efficacy of these vaccines. For example, the Pfizer-BioNTech and Moderna COVID-19 vaccines both use adjuvants to boost the body's immune response to the vaccine. This has driven the growth of the global vaccine adjuvants market in the short term.

However, with global travel restrictions and lockdowns in place, it was difficult to transport and distribute vaccine adjuvants. This has led to shortages of certain adjuvants, which has slowed down the development and production of some vaccines. For example, Bharat Biotech Covaxin faced supply chain disruptions due to the shortage of the adjuvant, which slowed down its distribution in some countries.

Russia Ukraine Conflict Analysis

The global market for vaccine adjuvants may be affected by the ongoing conflict between Russia and Ukraine, as Russia is a major provider of aluminum hydroxide, a commonly used adjuvant in vaccines. Disruptions in the supply chains of these adjuvants due to the conflict could lead to a shortage of vaccines that depend on them.

Segment Analysis

The global vaccine adjuvants market is segmented based on product type, route of administration, disease, end user, and region.

Particulate adjuvants segment to hold the highest market share in the global vaccine adjuvants market

The particulate adjuvants segment is expected to dominate and account fo a 30.2% global vaccine adjuvant market share over the forecast period. Delivery systems (particulate adjuvants) cover materials such as lipid particles, aluminum salts (alum), and microparticles. Alum is by far the most commonly used adjuvant. This adjuvant is in the formulation of licensed vaccines against diphtheria/tetanus/pertussis (DTP), Hepatitis A (HAV), and Hepatitis B (HBV).

Thereby, the increasing prevalence of infectious diseases, the growing demand for vaccines, and the need for more effective vaccines will result in the growth of this segment over the forecast period.

Geographical Analysis

The presence of major players to dominate the North America region.

North America is expected to have a dominant global vaccine adjuvants market share of around 1/3rd of this market, as the U.S. is the largest revenue contributor in North America due to the increasing elderly population, rising prevalence of cancers, high R&D for cancer diagnostics, and development of innovative products by manufacturers in the region.

Also, the presence of major players such as, in the U.S., GlaxoSmithKline (GSK) is a leading player in the vaccine adjuvants market. The company's AS03 adjuvant has been used in several vaccines, including the H1N1 flu vaccine and the Shingrix vaccine for shingles.

Competitive Landscape

The major global players in the market include: InvivoGen, OZ Biosciences, SEPPIC, SPI Pharma, Agenus, Inc, Aphios Corp, Vaxine Pty Ltd, Seqirus, Chemtrade, and Croda International.

Why Purchase the Report?

  • To visualize the global vaccine adjuvants market segmentation based on product type, route of administration, diseases, end user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of global vaccine adjuvants market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global vaccine adjuvants market report would provide approximately 53 tables, 54 figures and 195 pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Diseases
  • 3.4. Snippet by End User
  • 3.5. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of infectious disease to drive global vaccine adjuvant market growth during the forecast period
    • 4.1.2. Restraints
      • 4.1.2.1. High R&D cost for adjuvant development to hamper the market growth
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Particulate Adjuvants
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Adjuvant Emulsions
  • 7.4. Pathogen Components
  • 7.5. Combination Adjuvants
  • 7.6. Others

8. By Route of Administration

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 8.1.2. Market Attractiveness Index, By Route of Administration
  • 8.2. Intramuscular*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Oral
  • 8.4. Intradermal
  • 8.5. Subcutaneous
  • 8.6. Intranasal

9. By Diseases

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 9.1.2. Market Attractiveness Index, By Diseases
  • 9.2. Infectious Disease*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Cancer
  • 9.4. Others

10. By End User

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.1.2. Market Attractiveness Index, By End User
  • 10.2. Pharmaceutical and Biotech Companies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Research Institutes
  • 10.4. Others

11. By Region

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 11.1.2. Market Attractiveness Index, By Region
  • 11.2. North America
    • 11.2.1. Introduction
    • 11.2.2. Key Region-Specific Dynamics
    • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.2.7.1. The U.S.
      • 11.2.7.2. Canada
      • 11.2.7.3. Mexico
  • 11.3. Europe
    • 11.3.1. Introduction
    • 11.3.2. Key Region-Specific Dynamics
    • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.3.7.1. Germany
      • 11.3.7.2. The U.K.
      • 11.3.7.3. France
      • 11.3.7.4. Italy
      • 11.3.7.5. Spain
      • 11.3.7.6. Rest of Europe
  • 11.4. South America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. Brazil
      • 11.4.7.2. Argentina
      • 11.4.7.3. Rest of South America
  • 11.5. Asia-Pacific
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. China
      • 11.5.7.2. India
      • 11.5.7.3. Japan
      • 11.5.7.4. Australia
      • 11.5.7.5. Rest of Asia-Pacific
  • 11.6. Middle East and Africa
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Diseases
    • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

  • 12.1. Competitive Scenario
  • 12.2. Market Positioning/Share Analysis
  • 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

  • 13.1. InvivoGen*
    • 13.1.1. Company Overview
    • 13.1.2. Product Portfolio and Description
    • 13.1.3. Financial Overview
    • 13.1.4. Key Developments
  • 13.2. OZ Biosciences
  • 13.3. SEPPIC
  • 13.4. SPI Pharma
  • 13.5. Agenus, Inc
  • 13.6. Aphios Corp
  • 13.7. Vaxine Pty Ltd
  • 13.8. Seqirus
  • 13.9. Chemtrade
  • 13.10. Croda International

LIST NOT EXHAUSTIVE

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us